Findings in mice suggest that treatment with VEGF inhibitors prompts the upregulation of erythropoietin (Epo), a powerful cytokine and regulator of blood cell development. Could Epo be dulling the therapeutic effects of VEGF inhibition?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Carmeliet, P. Nature 438, 932–936 (2005).
Tam, B.Y.Y. et al. Nat. Med. 12, 793–800 (2006).
Willett, C.G. et al. J. Clin. Oncol. 23, 8136–8139 (2005).
Casanovas, O., Hicklin, D.J., Bergers, G. & Hanahan, D. Cancer Cell 8, 299–309 (2005).
Heeschen, C. et al. Blood 102, 1340–1346 (2003).
Kertesz, N., Wu, J., Chen, T.H., Sucov, H.M. & Wu, H. Dev. Biol. 276, 101–110 (2004).
Kamba, T. et al. Am. J. Physiol. Heart Circ. Physiol. 290, H560–H576 (2006).
LeCouter, J. et al. Science 299, 890–893 (2003).
Cleaver, O. & Melton, D.A. Nat. Med. 9, 661–668 (2003).
Hardee, M.E., Arcasoy, M.O., Blackwell, K.L., Kirkpatrick, J.P. & Dewhirst, M.W. Clin. Cancer Res. 12, 332–339 (2006).
Batra, S., Perelman, N., Luck, L.R., Shimada, H. & Malik, P. Lab Invest. 83, 1477–1487 (2003).
Yasuda, Y. et al. Br. J. Cancer 84, 836–843 (2001).
Leyland-Jones, B. et al. J. Clin. Oncol. 23, 5960–5972 (2005).
Stuben, G. et al. J. Cancer Res. Clin. Oncol. 127, 346–350 (2001).
Bohlius, J. et al. J. Natl. Cancer Inst. 98, 708–714 (2006).
Ribatti, D., Vacca, A., Roccaro, A.M., Crivellato, E. & Presta, M. Eur. J. Clin. Invest. 33, 891–896 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fischer, C., Carmeliet, P. & Conway, E. VEGF inhibitors make blood. Nat Med 12, 732–734 (2006). https://doi.org/10.1038/nm0706-732
Issue Date:
DOI: https://doi.org/10.1038/nm0706-732